Temozolomide for treating brain metastases

被引:51
作者
Abrey, LE
Christodoulou, C
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA
[2] Athens Med Ctr, Dept Med Oncol, Athens, Greece
关键词
D O I
10.1053/sonc.2001.26653
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The metastasis of solid tumors to the brain is associated with a poor prognosis despite aggressive treatment. Available treatment options are limited, as many chemotherapeutic agents do not penetrate the blood-brain barrier. Temozolomide (Temodar in the United States, Temodal globally; Schering Corporation, Kenilworth, NJ) is a novel chemotherapeutic agent with a good safety profile that crosses the blood-brain barrier and has shown activity against many human solid tumors. In two phase II trials of temozolomide in heavily pretreated patients with various solid tumor brain metastases, temozolomide was safe and generally well tolerated and showed clinical activity, with three partial responses and 19 disease stabilizations. Results of a third randomized phase II trial of concurrent administration of temozolomide and radiation therapy followed by adjuvant temozolomide therapy compared with radiation alone showed a higher rate of complete and partial responses (objective response of 96% v 67%) and significantly more complete responses (38% v 33%, P = .017), primarily in patients with newly diagnosed brain and lung metastases. Copyright © 2001 by W.B. Saunders Company.
引用
收藏
页码:34 / 42
页数:9
相关论文
共 21 条
[11]  
Johnson JD, 1996, NEUROSURG CLIN N AM, V7, P337
[12]   Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer? [J].
Kelly, K ;
Bunn, PA .
LUNG CANCER, 1998, 20 (02) :85-91
[13]  
KERSTEN M, 2000, P AN M AM SOC CLIN, V19, pA569
[14]   Brain metastases in breast cancer:: Prognostic factors and management [J].
Lentzsch, S ;
Reichardt, P ;
Weber, F ;
Budach, V ;
Dörken, B .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (04) :580-585
[15]  
Nussbaum ES, 1996, CANCER-AM CANCER SOC, V78, P1781, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1781::AID-CNCR19>3.0.CO
[16]  
2-U
[17]   CISPLATIN INCREASES SENSITIVITY OF HUMAN LEUKEMIC BLASTS TO TRIAZENE COMPOUNDS [J].
PICCIONI, D ;
DATRI, S ;
PAPA, G ;
CARAVITA, T ;
FRANCHI, A ;
BONMASSAR, E ;
GRAZIANI, G .
JOURNAL OF CHEMOTHERAPY, 1995, 7 (03) :224-229
[18]  
SUMMERS Y, 1999, P AN M AM SOC CLIN, V18, pA531
[19]   Prognosis of patients treated for intracranial metastases with whole-brain irradiation [J].
Sundström, JT ;
Minn, H ;
Lertola, KK ;
Nordman, E .
ANNALS OF MEDICINE, 1998, 30 (03) :296-299
[20]  
Wronski M, 1997, CANCER, V80, P1746, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1746::AID-CNCR8>3.0.CO